Neuroendocrinology News

Adults with congenital adrenal hyperplasia receiving an oral corticotropin-releasing factor type 1 receptor antagonist had a greater reduction in daily glucocorticoid dose at 24 weeks than placebo, according to top-line phase 3 trial data.

More than 80% of adults with acromegaly achieved an insulin-like growth factor level at or below the upper limit of normal at 36 weeks with an investigational once-daily oral medication, according to topline results from a phase 3 trial.

Adults with endogenous Cushing’s syndrome reported that the condition moderately affects their quality of life and causes them to have symptoms about 16 days in a given month, according to findings published in Pituitary.

Cardiometabolic comorbidities, such as hypertension, cardiac arrythmias and diabetes, are more common in adults with acromegaly than those without the condition, according to a systematic review and meta-analysis published in Pituitary.

The FDA in June approved a once-weekly human growth hormone analog for children aged 3 years and older with growth hormone deficiency, according to a company press release.

More than half of adults with acromegaly receiving the somatostatin receptor ligand pasireotide achieved normal insulin-like growth factor I levels, according to data from a long-term real-world study.

Márta Korbonits, MD, PhD, DSc, FRCP, uncovered a passion for endocrinology from a series of inspirational lectures during her medical training.

CHICAGO —In this video exclusive, John Carmichael, MD, discusses some of the pituitary research presented at ENDO 2023, including treatments for Cushing’s syndrome and adipose effects following acromegaly cure.

CHICAGO—In this video exclusive, Tamara Wexler, MD, PhD, discusses evaluation and treatment of pituitary hormone deficiencies that can occur after acquired brain injury, from mild to severe concussions.

R. Scott Struthers, PhD, had a lab job synthesizing peptide hormones as a college freshman. That experience launched a career featuring discovery of novel agents for endocrine diseases, women’s health conditions and cancers.